Doxycycline in early CJD: a double-blinded randomised phase II and observational study

Area of Science:

• Neuroscience
• Pharmacology
• Infectious Diseases

Background:

• Sporadic Creutzfeldt-Jakob disease (sCJD) is a fatal neurodegenerative prion disease.
• Current treatment options for sCJD are limited.
• Doxycycline, a tetracycline antibiotic, has shown potential in preclinical models of prion diseases.

Purpose of the Study:

• To evaluate the therapeutic efficiency of doxycycline in patients with sporadic Creutzfeldt-Jakob disease (sCJD).
• To assess the impact of doxycycline on survival in sCJD patients through a double-blinded, randomized phase II study and compassionate use data.

Main Methods:

• Recruitment of patients with probable or definite sCJD from a national reference center.
• A double-blinded, randomized phase II study (EudraCT 2006-003934-14) with oral doxycycline.
• Analysis of compassionate use data for sCJD patients treated with doxycycline.
• Meta-analysis combining results from both study groups.
• Evaluation of factors influencing survival, including age, gender, codon 129 polymorphism, and cognitive function.

Main Results:

• A meta-analysis combined data from a phase II study (7 treatment vs. 5 control) and compassionate use data (55 treatment vs. 33 control).
• A statistically significant (p=0.049) slight increase in survival time was observed in the doxycycline treatment group (HR=0.63; 95% CI 0.402 to 0.999).

Conclusions:

• Doxycycline demonstrated a potential to slightly increase survival in sCJD patients.
• A larger clinical trial is warranted to confirm the therapeutic efficacy of doxycycline, particularly in the early stages of sCJD.